Sarcoma  >>  cisplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT02784795: A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Completed
1b
94
Europe, US
LY3039478, Taladegib, LY2940680, Abemaciclib, LY2835219, Cisplatin, Gemcitabine, Carboplatin, LY3023414
Eli Lilly and Company
Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
08/18
02/20
NCT02029690: Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Terminated
1
85
Europe, US
ADI-PEG 20
Polaris Group
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
08/18
06/20
NCT02897375: Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Completed
1
71
US
Carboplatin, Paraplatin, Cisplatin, CDDP, Cis-diamminedichloridoplatinum, Cisplatinum, Cismaplat, Neoplatin, Palbociclib, Ibrance, PD-0332991
Emory University, Pfizer, National Institutes of Health (NIH), National Cancer Institute (NCI)
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
10/21
10/21
NCT04861948: IBI188 Combination Therapy in Solid Tumors

Terminated
1
9
RoW
IBI188, GM-CSF, Cisplatin/Carboplatin, Bevacizumab, Sintilimab, Pemetrexed
Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumors, Lung Adenocarcinoma, Osteosarcoma
07/22
07/22
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
240
US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx, Inc.
Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors
12/25
07/26

Download Options